The subject of Cannabinoids has been in many headlines recently. Nearly a century after it was listed as a prohibited substance in the United States and elsewhere, there is now a gradual shift towards acceptance—both medicinally and recreationally. Clearly, there is an important trend developing.
A team of Derwent IP experts recently conducted an analysis studying the shift toward deregulation and acceptance of Cannabinoids focusing on the impact on innovation as measured in patent filings.
Here’s what you will find this report:
- What new innovation opportunities are being created by deregulation
- Which companies hold the strongest cannabinoids portfolios
- How patent analytics provides valuable insight into the cannabinoids landscape
- Exploration of individual inventions by therapeutic target and type of active cannabinoid